Mechanisms of new antiepileptic drugs.
Taylor
C P
CP
Parke-Davis Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105, USA.
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004345:Drug Industry; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D018079:Receptors, GABA / Q000378:metabolism; D011963:Receptors, GABA-A / Q000187:drug effects; D026941:Sodium Channel Blockers; D005680:gamma-Aminobutyric Acid / Q000493:pharmacokinetics
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D018079:Receptors, GABA; D011963:Receptors, GABA-A; D026941:Sodium Channel Blockers; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin